BIODESIX, INC. (BDSX)

Every figure this model derived for BDSX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 412,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 29,996,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 43,565,000 AssetsCurrent 2026-06-30
current liabilities 15,291,000 LiabilitiesCurrent 2026-06-30
equity 9,144,000 StockholdersEquity 2026-06-30
interest expense 8,092,000 InterestExpense 2026-06-30
ocf -19,831,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 102,939,000 Revenues 2026-06-30
sbc 4,063,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up BDSX on one particular measure came for.

RatioValue
cash operating margin-10.66
current ratio2.89
current ratio reported2.85
deferred revenue growth-66.77
dilution pct16.72
fcf margin-19.67
growth cv1.44
interest cover-2.55
operating margin-20.02
owner earnings margin-23.61
revenue growth34.46
revenue growth per share15.2
roic-55.85
rule of 4014.44
sbc pct revenue3.95

What to be careful about

What this model itself distrusts about BDSX's figures. Written by the derivation as it ran, not added afterwards.